Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
10 hedge funds and large institutions have $10.4M invested in Parnell Pharmaceuticals Holdings Ltd in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 5 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
29% less funds holding
Funds holding: 14 → 10 (-4)
31% less capital invested
Capital invested by funds: $14.9M → $10.4M (-$4.57M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| 1 |
BlackRock
New York
|
+$474K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$113K |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$108K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$59.2K |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
+$21.3K |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$580K |
| 2 |
PA
Perceptive Advisors
New York
|
-$341K |
| 3 |
Goldman Sachs
New York
|
-$13.5K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $2.81M | – | – | – |
|
|
BA
2
BlackRock Advisors
Wilmington,
Delaware
| $1.96M | +$108K | +25,472 | +5% |
|
|
AG
3
Artal Group
Luxembourg
| $1.72M | – | – | – |
|
|
ECM
4
Endurant Capital Management
San Mateo,
California
| $1.49M | +$113K | +26,723 | +7% |
|
|
BG
5
BlackRock Group
London,
United Kingdom
| $792K | +$21.3K | +5,017 | +2% |
|
|
6
Alyeska Investment Group
Chicago,
Illinois
| $763K | +$59.2K | +13,935 | +7% |
|
|
7
BlackRock
New York
| $384K | +$474K | +111,588 | New |
|
|
BIM
8
BlackRock Investment Management
Wilmington,
Delaware
| $318K | +$12.6K | +2,962 | +3% |
|
|
9
Goldman Sachs
New York
| $127K | -$13.5K | -3,190 | -8% |
|
10
UBS Group
Zurich,
Switzerland
| $13K | +$2.98K | +702 | +24% |
|
|
11
JP Morgan Chase
New York
| – | -$580K | -117,170 | Closed |
|
|
PA
12
Perceptive Advisors
New York
| – | -$341K | -68,800 | Closed |
|
|
LTFS
13
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -300 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$1K | -131 | Closed |
|
PARN Hedge Fund Activity: Q3 2015 in Review
10 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q3 2015, worth a combined $10.4M — down 31% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PARN and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was BlackRock, opening a new position worth an estimated $474K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $580K sold.
- 10 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q3 2015, down from 14 in Q2 2015.
- Funds reported $10.4M of Parnell Pharmaceuticals Holdings Ltd stock for Q3 2015, down 31% quarter-over-quarter.
- 1 fund opened new Parnell Pharmaceuticals Holdings Ltd positions in Q3 2015 and 5 closed out, a net change of -4 holders.
- The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q3 2015 was BlackRock, an estimated $474K added.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q3 2015 was JP Morgan Chase, an estimated $580K sold.
Based on aggregated 13F filings for Q3 2015.